• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pfizer Inc.

Pfizer to absorb Mylan in off-patent drug spinout

July 29, 2019 By Brad Perriello

Pfizer to merge Upjohn with Mylan

Pfizer (NYSE:PFE) plans to absorb Mylan (NSDQ:MYL) as part of the spinout of its Upjohn off-patent drugs business in an all-stock deal. The deal, structured to avoid taxes on any gains from the spinout, would see each Mylan share converted into a share of the as-yet-unnamed new company. Pfizer stockholders would then own 57% of […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Mylan, Pfizer Inc.

Teva launches generic for Pfizer’s Flector pain patch

March 4, 2019 By Sarah Faulkner

Teva Pharmaceuticals - updated logo

Teva (NYSE:TEVA) said last week that it launched a generic version of Pfizer‘s (NYSE:PFE) Flector diclofenac epolamine patch. Using a nonsteroidal anti-inflammatory drug, the topical patch is designed to treat acute pain due to minor strains, sprains and contusions. Pfizer’s Flector patch garnered annual sales of $123 million in the U.S. as of Dec. 2018, according […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Pfizer Inc., Teva Pharmaceuticals

Report: Pharma companies kick off new year with price hikes

January 2, 2019 By Sarah Faulkner

Prescription drugs

Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Allergan (NYSE:AGN) topped the list, raising the […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Biogen, Bristol-Myers Squibb Co., Eli Lilly & Co., Pfizer Inc.

FDA warns of flesh-eating genital infection linked to diabetes drug

August 31, 2018 By Fink Densford

FDA

The FDA this week warned of serious flesh-eating bacterial infections, or necrotizing fasciitis, reported by patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors intended for treating type 2 diabetes. The federal watchdog said that between March 2013 and May 2018, 12 cases of Fournier’s gangrene, a rare but life-threatening bacterial infection of the tissue under the skin […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly & Co., johnsonandjohnson, Merck, Pfizer Inc.

Sage Therapeutics’ chief scientist on discovering drugs and taking risks

June 29, 2018 By Sarah Faulkner

Sage Therapeutics

When Al Robichaud got his start as a medicinal chemist in 1991, he knew that discovering and developing drugs meant shouldering some level of risk. But around 2011, it became clear that the process for developing brain drugs was too costly and risky for major pharmaceutical companies to justify pursuing, as companies including Novartis (NYSE:NVS), GlaxoSmithKline (NYSE:GSK), […]

Filed Under: Discovery, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: GlaxoSmithKline plc, Novartis, Pfizer Inc., sagetherapeutics, Sanofi-Aventis

Hospira issues nationwide recall for opioid overdose reversal drug

June 6, 2018 By Sarah Faulkner

Pfizer

Pfizer‘s (NYSE:PFE) Hospira unit this week voluntarily recalled two lots of a drug used to reverse the course of an opioid overdose. The company’s naloxone injection, sold in its Carpuject single-use cartridge syringe, was recalled due to the potential presence of embedded and loose particulate matter in the plunger. Hospira specifically warned that products from lots 72680LL and 76510LL […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Recalls, Wall Street Beat Tagged With: Hospira Inc., Pfizer Inc.

Report: Pharma companies ask Supremes to take eye-dropper case

April 2, 2018 By Sarah Faulkner

gavel

A group of pharmaceutical companies, including Allergan (NYSE:AGN) and Merck (NYSE:MRK), have asked the Supreme Court to review a case between the industry players and patients regarding the design of the companies’ eye-droppers, according to a report from the AP. In the on-going legal debate, patient groups have claimed that the companies’ devices dispense large drops of medication […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Merck, Pfizer Inc.

Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies

January 30, 2018 By Sarah Faulkner

National Institutes of Health logo

The National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition. Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Celgene, GlaxoSmithKline plc, michaeljfoxfoundation, National Institutes of Health, Pfizer Inc., Sanofi-Aventis, Verily

EpiPen shortage in Canada to last until March

January 19, 2018 By Sarah Faulkner

EpiPen

Pfizer Canada (NYSE:PFE) has warned Health Canada that there is a shortage of 0.3 mg EpiPen auto-injectors due to a manufacturing disruption. The company, which licenses the emergency allergy treatment from Mylan (NSDQ:MYL), reported that the problem should be resolved by March 2. There are no alternative auto-injectors available on the market in Canada for patients at […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Mylan, Pfizer Inc.

How this biotech plans to go up against big pharma with its eye disease products

December 29, 2017 By Sarah Faulkner

Ocugen

Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Massachusetts Eye & Ear Infirmary, ocugen, Pfizer Inc., Regeneron, Roche, Shire

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 5
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS